Background {#Sec1}
==========

Digoxin is widely prescribed for the treatment of congestive heart failure and atrial fibrillation. Therapeutic drug monitoring of digoxin is recommended because of its narrow therapeutic range \[[@CR1], [@CR2]\]. Previous studies have reported several equations and nomograms to enable physicians to determine the appropriate dosage of digoxin for individual patients \[[@CR3], [@CR4]\]. In addition, population pharmacokinetic data indicate that clearance of digoxin is influenced by demographic variables such as age, total body weight, and serum creatinine levels \[[@CR5]--[@CR7]\]. However, population pharmacokinetics have not been studied thus far to evaluate the influence of concomitant administration of drugs such as amiodarone, verapamil, and tolvaptan on relative digoxin clearance. Recently, the therapeutic range for digoxin in patients with heart failure with a normal sinus rhythm has been revised to a low and narrow range (0.5--0.8 ng/mL) based on the findings from the digitalis investigation group trial \[[@CR8]\]. In this study, we aimed to analyze the population pharmacokinetics of digoxin in the presence of concomitant administration of other drugs. Furthermore, we determined initial dosing regimens to achieve concentrations (0.5--0.8 ng/mL) according to our population pharmacokinetic data.

Methods {#Sec2}
=======

Ethics statement {#Sec3}
----------------

Blood samples were collected as part of the routine patient care for therapeutic drug monitoring and laboratory testing when we collect blood samples from patients. This study was approved by the Ethics Committee of Kitasato University Hospital (B13-99: approved on July 24, 2013).

Data source {#Sec4}
-----------

Routine clinical pharmacokinetic data (287 observations) were retrospectively collected from 192 adult patients who were administered digoxin (Digosin®; Chugai Pharmaceutical Co. Ltd, Tokyo, Japan or Digoxin-KY®; Toaeiyo Pharmaceutical Co Ltd, Tokyo, Japan) at Kitasato University Hospital between November 2011 and January 2013. The clinical characteristics of patients in this study were shown in Table [1](#Tab1){ref-type="table"}. The patients were inpatients and outpatients. Inpatients were under the supervision of medical and nursing staff. As for outpatients, we checked their doctor's or nurse's medical records for patients' compliance and digoxin trough concentration samples. If this information wasn't written in medical records, the patient was excluded. Compliance was standardized, and digoxin concentrations were determined. Blood samples were obtained before the administration of the medication. Patient information is provided in Table [1](#Tab1){ref-type="table"}. The collected data included age, gender, height, body weight (BW), serum creatinine level, creatinine clearance (CLcr), ejection fraction (EF), serum potassium level, concomitant medication, and serum concentration of digoxin. Concomitant medication xadministrated in the previously reported to influence digoxin pharmacokinetics were investigated. CLcr was estimated from the serum creatinine level using the Cockcroft-Gault method \[[@CR9]\]. One week after administration of digoxin, steady-state concentrations were achieved; subsequently, we drew blood samples before the morning dosing for the assay. The concentration of digoxin was measured using a cloned enzyme immunoassay. The minimum detectable concentration for digoxin was 0.2 ng/mL. The coefficients of variation of both intra- and inter-assay precision were less than 10 %. The present study excluded patients who had any major disorders of the hepatic, gastrointestinal, dialysis or rapidly deteriorating renal function.Table 1Patient characteristicsNumber of Patients192Gender (Male:Female)121:71EF (%) (\>=40: \<40)156:36Age (year)71±12^\*^CLcr (mL/min)56.17±33.76^\*^Weight (kg)55.47±11.94^\*^Observation2870.125 mg /3 days70.125 mg /2 days170.0625 mg /day140.125 mg/day2000.25 mg/day49Digoxin concentration (ng/mL)0.90±0.56^\*^Combination medicationAmiodarone15Amlodipine21Atorvastatin14Azelnidipine13Bisoprolol28Carvedilol53Nifedipine13Spironolactone35Tolvaptan8Antiarrhythmic agent; Class I12(Aprindine, Cibenzoline, Flecainide, Pilsicainde, Procainamide)Antiarrhythmic agent;Class IV31(Bepridil, Diltiazem, Verapamil)\*Mean ± standerd deviationEF; Ejunction function, CLcr; Creatine clearance

Pharmacokinetics model {#Sec5}
----------------------

Data analysis was performed using the nonlinear mixed effects model (NONMEM) program (version VI, level 1.0) developed by Beal and Sheiner \[[@CR10]\]. Because the trough serum concentration of digoxin achieved steady-state, we used a simple pharmacokinetic model as follows: Cssij = Dij/(CLij τij), where Cssi is the steady-state serum digoxin concentration measured in the jth patient while he or she received the ith dosage, Dij is the dosage of digoxin in the jth patient, CLij is the total body clearance of digoxin in the jth patient, and τij is the dosing interval for the ith dosage in the jth patient. We used the first-order conditional estimation method (FOCE) for modeling. The inter-individual variability of the parameters was assessed using an exponential error model: Pi = TV(Pi) × exp(ηi), where Pi indicated the individual value, TV(Pi) was the population value for the parameters described in the equation, and ηi was the random deviation of Pi from TV(Pi). The value of ηi was assumed to be independently and normally distributed with a mean of 0 and a variance of ω2. The residual (intra-individual) variability of the parameters was assessed using a proportional error model: Cobs,ij = Cpred,ij × (1 + εij), where Cobs,ij and Cpred,ij denote the j^th^ observed and predicted concentrations for the i^th^ subject, respectively, and ε is a random intra-individual error that is normally distributed with a mean of 0 and variance σ2.

Covariate analysis {#Sec6}
------------------

We examined the covariance of the variables, including age, CLcr, BW, EF, systolic blood pressure, and concomitant use of drugs to improve the population pharmacokinetic model. The influence of continuous covariates on the pharmacokinetic parameter TV(P) was modeled according to the following equations: TV(P) = θp + θc × (covariance), and TV(P) = θp × θc^(covariance)^. The covariance that showed a correlation with the pharmacokinetic parameters was introduced into the model. The significance of the influence of covariates was evaluated by a change of -2 log likelihood (the minimum value of the objective function: OBJ). An OBJ decrease of more than 3.84 from the basic structural model (*χ*2: degree of freedom = 1, *P* \< 0.05) was considered statistically significant during the forward inclusion process. The full model was structured by incorporating the significant covariates, and the final model was developed using a backward elimination method. When one covariate factor was excluded from the full model, an OBJ that increased more than 6.63 from the full model (*χ*2: degree of freedom = 1, *P* \< 0.01) was considered statistically significant.

Model evolution {#Sec7}
---------------

The adequacy of fitting was examined by plotting the predicted concentration versus the observed concentration, individual predicted concentration after Bayesian step versus observed concentration, and the weighted residual concentration versus the predicted one. The accuracy and robustness of the final model were assessed using the bootstrap method \[[@CR11]\]. A bootstrap sample was generated by repeated random sampling of the original data set, and the size of the bootstrap sample was the same as that of the original sample. We reconstructed 200 bootstrap samples, and the final model was determined by repeatedly testing the 200 bootstrap samples. The mean parameter estimates obtained from replication and calculated normally were compared with those obtained from the original data set.

Determination of the dosing regimen {#Sec8}
-----------------------------------

Simulation of pharmacokinetics was performed to determine the dosing regimen based on our population pharmacokinetics data. Digoxin concentration was simulated for 1000 patients by using the final population pharmacokinetics model.

The probability that the trough digoxin concentration was in the range of 0.5--0.8 ng/mL in the steady state was calculated as the ratio of the number of simulated patients to the total number of patients. The simulation was performed using Microsoft Excel® 2013.

Results {#Sec9}
=======

The serum concentration of digoxin as a function of the daily dose and each covariate model is shown in Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}, respectively. CLcr, BW, amiodarone, amlodipine, atorvastatin, bisoprolol, carvedilol, and tolvaptan were significant covariates for the CL of digoxin. During the backward deletion from the full model, CLcr and amiodarone remained in the model that caused significant OBJ increase. Therefore, the final model was as follows: CL/F (L/h) = (1.21 + 0.0532 × CLcr \[mL/min\]) × (1 + 0.787 × AMD), where AMD = 0 for concomitant administration of amiodarone or 1 otherwise.Fig. 1Relationship between the dose of digoxin and serum concentrationTable 2Hypothesis testing for fixed effect model of digoxin pharmacokineticsFixed modelOBJLLD*p*-valueCL=θ1−128.969θ1+θ2×CLcr−331.151202.182\<0.001θ1+θ2×BW−139.20310.234\<0.002θ1×θ2^Ejection\ function^ (EF\>41=1,EF\<40=0)−129.2470.278N.S.θ1×θ2^Age^ (Age\>65=0,Age\<64=1)−131.5082.539N.S.θ1×θ2^Drug^ (0;Cocomitant adminstaraion,1;otherwise)Amiodarone−163.26034.291\<0.001Amlodipine−142.55213.583\<0.001Atorvastatin−135.9857.016\<0.01Azelnidipine−129.0160.047N.S.Bisoprolol−145.97117.002\<0.001Carvedilol−134.1905.221\<0.05Nifedipine−129.3550.386N.S.Spironolactone−132.1773.208N.S.Tolvaptan−133.8044.835\<0.05Antiarrhythmic agent;Class I (Aprindine,Cibenzoline, Flecainide,Pilsicainde,Procainamide)−131.6642.695N.S.Antiarrhythmic agent;Class IV (Bepridil,Diltiazem,Verapamil)−131.5592.590N.S.*OBJ* the minimum value of objective function, *LLD*-2 log-likefood difference, *N.S* not significant

The coefficient of variation (CV) of the inter-individual variability (ω^2^) of CL and the residual variability (σ^2^) were 32.2 and 25.5 %, respectively (Table [3](#Tab3){ref-type="table"}). Assessment of the predictive performance of the final model is presented in scatter plots of the observed concentration versus the population-predicted concentration (Fig. [2a](#Fig2){ref-type="fig"}) and the individual-predicted concentrations of digoxin (Fig. [2b](#Fig2){ref-type="fig"}). Weighted-residual concentration versus the population predicted concentration is shown in Fig. 2c. The plots were symmetrically distributed around the line of identity, which indicated that the model adequately described the serum concentration of digoxin. In the bootstrapping analysis of the final model, 180 of 200 showed successful results and the values of parameters used in the final model generated from the bootstrap analysis were similar to those of the developed model (Table [4](#Tab4){ref-type="table"}).Table 3Final estimates for the population pharmacokinetic parameters of digoxinPopulation mean parametersCL(L/h)= (1.21+0.0532×CLcr(mL/min)) ×(1+0.787×AMD)(AMD = 0 for cocomitant adminstarion of amiodarone, otherwise 1)Interindividual varianceω(CL)=32.2 %Intraindividual varianceσ=25.5 %Fig. 2**a** Population predicted concentrations from the final model; (**b**) Individual predicted concentrations from the final model. **c** Individual predicted concentrations from the final model. Scatter plot of weighted residuals (WRES) versus predicted concentrationTable 4Results of bootstrap validationParameterFinal Model^a^Bootstrap^b^95% Confidence intervalMean ± S.E.Mean ± S.E.\[Lower, Upper\]θ11.21 ± 0.211.30 ± 0.05\[1.20-1.39\]θ20.0532 ± 0.00680.0543 ± 0.0016\[0.050-0.057\]θ30.787 ± 0.1870.803 ± 0.018\[0.768-0.838\]ωCL0.104 ± 0.0170.324 ± 0.006\[0.312-0.336\]σ0.065 ± 0.0100.340 ± 0.086\[0.171-0.509\]CL=(θ1+θ2×CLcr)×(1+θ3×AMD)^a^ Obtained from the original data set^b^ Calculated from 200 bootstrap replicates(180 convergence)

We used the final model and performed a simulation to determine the dosing regimen in patients with renal impairment and in those with concomitant administration of amiodarone. Digoxin concentration was simulated for 1000 patients with CLcr ranging from 5 to 130 mL/min with or without amiodarone administration. The simulation was performed for dosages ranging from 0.0625 mg/every 2 days to 0.25 mg/day. The probabilities of trough digoxin concentrations being in the range of 0.5--0.8 ng/mL in the steady state are shown in Fig. [3](#Fig3){ref-type="fig"}. The typical initial dose of digoxin at various CLcr with or without amiodarone based on simulation experiments is shown in Fig. [4](#Fig4){ref-type="fig"}.Fig. 3Probability (%) of trough concentration of digoxin being within 0.5--0.8 ng/mL at CLcr ranging from 5 to 130 mL/min with amiodarone (**a**) or without administration (**b**)Fig. 4Nomogram for target serum digoxin concentration. The proposed nomograms are presented as a target serum digoxin concentration of 0.5--0.8 ng/mL

Discussion {#Sec10}
==========

To our knowledge, this is the first study in which a dosing regimen based on population pharmacokinetics has been proposed. We analyzed the sampling data for digoxin obtained from routine clinical data by using the NONMEM. This study focused on how drugs interact with digoxin. Our results showed that amiodarone and CLcr were significant covariants for the systemic clearance of digoxin. The systemic clearance consists of elimination rate constant and distribution volume. However, our model can't individually assess these parameters because our data is trough concentration sampling. The rate constant is mainly affected by creatinine clearance and amiodarone. Typically, digoxin is thought to be eliminated by the kidney. Additionally, previous studies showed that CLcr is an affective factor \[[@CR5]--[@CR7]\]. Regarding drug interactions, amiodarone, but not amlodipine, atorvastatin, bisoprolol, carvedilol, or tolvaptan, remained during the backward deletion. Beta blockers such as bisoprolol and carvedilol increase the maximum plasma concentration of digoxin by about 1.3-fold \[[@CR12]\]. Similarly, administration of 10 mg atorvastatin increases the maximum plasma concentration of digoxin by about 1.2-fold \[[@CR13]\]. Administration of 60 mg tolvaptan increases the maximum plasma concentration of digoxin by about 1.3-fold \[[@CR14]\]. Schwartz JB reported that amlodipine does not significantly influence steady-state digoxin concentrations \[[@CR15]\]. Chen R \[[@CR5]\] and Yukawa E \[[@CR6]\] showed that spironolactone and calcium channel blockers affect the clearance of digoxin. However these factors result in about a 20 % decrease in digoxin clearance, and also these studies didn't examine amiodarone. Therefore, we concluded that these medications were not included as final factors. Amiodarone increased the trough level of digoxin concentration by approximately two-fold \[[@CR16]\]. The main reason that amiodarone increases the serum concentration of digoxin is the inhibition of digoxin secretion from renal tubules and the inhibition of the P-glycoprotein membrane transporter system \[[@CR17]\]. Our results showed that the population means showed a good predictive performance. The final model lacked bias, despite the drug concentration and the observed drug concentration being almost identical to the individual predicted concentration after the Bayesian steps. The weighted residuals were acceptable to within three standard deviations, which are generally recognized as criteria for no selection biases. In addition, the convergence ratio on bootstrap data was significantly high (Table [4](#Tab4){ref-type="table"}). Thus, the robustness of the model was sufficiently confirmed. The difference between θ of the final model estimate and that of the bootstrap means was relatively small. Therefore, we concluded that the final model had a good predictive performance. In future studies, we will perform external validation for our new population pharmacokinetics model. The probability of the trough concentration of digoxin being in the therapeutic range of 0.5--0.8 ng/mL for congestive heart failure is shown in Fig. 3. This regimen suggests the typical initial dosage of digoxin in patients at various CLcr with co-administration of amiodarone. The different initial dosages of digoxin calculated using the Koup \[[@CR18]\] and Jusko \[[@CR19]\] method depending on different values of CLcr to achieve a target digoxin concentration of 0.7 ng/mL were as follows: CLcr \< 30 mL/min, start at 0.0625 mg every day; CLcr 30--80 mL/min, start at 0.125 mg every day; and CLcr \> 120 mL/min, start at 0.25 mg every day. In addition, Bauman JL et al \[[@CR4]\] reported a nomogram for achieving a steady-state concentration of 0.7 ng/mL on the basis of creatinine clearance and IBW or height. These findings are similar to those obtained using our new dosing regimen without amiodarone. This initial dosage regimen will be useful for reasonable therapies using oral digoxin for congestive heart failure. Some limitations exist in this study. Some studies have shown that the serum concentration of digoxin increases after concomitant administration with other antiarrhythmic drugs such as verapamil and bepridil \[[@CR20], [@CR21]\]. We did not include these factors because very few patients in our study received concomitant administration of these drugs. Additionally, we didn't examine the effect of digoxin transportation role of P-glycoprotein inhibitors such as itraconazole, cyclosporine and clarithromycin \[[@CR22]--[@CR24]\] because these medicines are not administered. Therefore our nomogram is not adapted with concomitant with these medications. Our population model didn't consider volume of distribution or absorption phase. Therefore our model didn't simulate these phase. A prospective study using this regimen is necessary to investigate the robustness and reliability of our model.

Conclusion {#Sec11}
==========

Our results suggested that these dosage regimens would provide maximum therapeutic benefit of digoxin, and achieve the overall goal of reducing the toxicity in patients in whom the dosage of digoxin exceeds the therapeutic range.
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